Stockreport

ArriVent BioPharma Reports Full Year 2024 Financial Results

ArriVent BioPharma, Inc.  (AVBP) 
PDF First clinical data demonstrating robust confirmed responses and CNS anti-tumor activity for firmonertinib in first-line NSCLC EGFR PACC mutationsGlobal pivotal Phase 3 [Read more]